Certain Common Stock of Zentalis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026.

ZNTL - Late Stage Ovarian Cancer Trials And Extended Cash Runway Will Support Future Upside Potential

Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating

Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

At $2.18 a share, Ingmar Bruns acquires 9,727 shares in Zentalis Pharmaceuticals (ZNTL).

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

Zentalis Pharmaceuticals stock falls on public offering news

$ZNTL stock is down 15% today. Here's what we see in our data.

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?